We are excited to announce that Eagle IP will be returning as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Spring conference in Boston. Our President and Managing Director, Ms. Jennifer Che, is one of the distinguished speakers at the event. Organized by Life Sciences Intellectual Property Review, this event will take place on May 6-7, 2025, at the Hyatt Regency Boston located at One Avenue de Lafayette, Boston, MA 02111.

Come join us there and meet us at our booth!

Every year, LSPN brings together experts from pharmaceutical, biotech, and medtech industries to discuss innovation and IP protections. The conference covers patentability, eligibility, prosecution, and litigation, offering insights for the entire patent protection lifecycle in the US.

For more information about the conference and to complete your registration, please visit: https://www.lspnnorthamerica.com

If you won’t be able to attend LSPN but will be in Boston and would like to schedule a meeting, please let us know. We would be happy to arrange a convenient time to connect.

We are looking forward to seeing you in Boston!

我们的过去活动

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Recommended Insights

Stay Ahead: Getting a Chinese Patent in Three Months?

2024年4月23日
The China National Intellectual Property Administration (CNIPA) has announced a significant development in the realm of patent prosecution: the initiation of the "PPH Improvement Initiative" in collaboration with key patent offices from the United States, Europe, Japan, and South Korea. This initiative aims to elevate the user experience of the Patent Prosecution Highway (PPH) by […]
阅读更多 >

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
阅读更多 >

China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH

2020年7月20日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
阅读更多 >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
阅读更多 >
Top crossarrow-right